Threshold Pharmaceuticals (THLD) Presents Positive TH-302 Preclinical Results

April 20, 2009 8:49 AM EDT

Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) announced multiple preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research (AACR) Annual Meeting, being held April 18 to 22, 2009, at the Colorado Convention Center in Denver, CO.

"While these results are preclinical, they are very encouraging to us," said Charles Hart, Ph.D., Threshold's vice president of biology. "Especially encouraging is the superior efficacy and less toxicity observed with TH-302 compared to ifosfamide in human lung cancer models."

Poster 4517 (TH-302, a novel hypoxia-activated prodrug, shows superior efficacy and less toxicity than ifosfamide in metastatic and ectopic human lung carcinoma models) indicates that TH-302 has superior activity and less toxicity than ifosfamide in two preclinical models. Efficacy endpoints included tumor growth inhibition and survival and toxicity endpoints included body weight loss and myelosuppression. The therapeutic index of TH-302 was greater than ifosfamide. These results are consistent with the initial data presented at the EORTC conference in October last year where interim Phase 1 clinical trial results in patients with solid tumors demonstrated very little myelosuppression as well as some anti-tumor activity.

Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!

Related Categories

Corporate News
FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?